Glp-1 weight loss denied as not FDA-approved for this use by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna Denied This GLP-1 for Weight Loss: "Not FDA-Approved"

This denial usually means one of two things: Cigna concluded the specific GLP-1 medication prescribed is not approved by the FDA for a chronic weight-management indication, or that your documented diagnosis does not align with the approved indication the drug carries. This is a technical classification denial — and it is frequently wrong or incompletely applied, making it worth a full appeal.

## Why It Is Appealable

Several GLP-1 receptor agonists do hold FDA approval specifically for chronic weight management in adults, distinct from their diabetes approvals. If your prescriber ordered a GLP-1 that carries that approval and your diagnosis matches the labeled indication, Cigna's characterization of "not FDA-approved" is factually incorrect as applied to your claim. Even where an off-label element exists, off-label use of an FDA-approved drug is legal medical practice and, under many plan designs, must be covered when supported by recognized clinical evidence.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full and fair internal review. Cigna must respond within the timeframe set by your plan documents (typically 60 days for post-service, 30 days for pre-service).
• External review: After exhausting internal appeal, or if Cigna fails to respond in time, you may request independent external review under ACA §2719. The standard window is approximately four months from the date of the denial notice. An expedited external review is available when delay would seriously jeopardize your health.
• State protections: Depending on your state, additional consumer protections may apply; check your state insurance commissioner's website.

## Documentation to Gather

1. Diagnosis confirmation: Chart notes establishing your obesity or overweight diagnosis with related comorbidities, using your treating provider's language. 2. FDA labeling: Print the current FDA-approved prescribing information (label) for the exact drug and strength prescribed. Highlight the indication section that covers chronic weight management. 3. Prescriber letter: A detailed medical-necessity letter from your prescriber explaining why the prescribed drug is appropriate for your FDA-recognized indication, citing the label directly. 4. Prior treatment history: Dates, durations, and outcomes of any prior weight-management interventions Cigna may require as prerequisites. 5. Clinical records: Relevant labs, vitals, and progress notes that substantiate the clinical picture described in the prescriber letter.

## Criteria-Mapping Structure

Create a two-column table. In the left column, copy each coverage requirement Cigna listed in the denial letter — including any reference to FDA indication. In the right column, provide the specific chart fact or document that satisfies each requirement. Attach the FDA label's indication section directly and cross-reference it in your cover letter. This mapping forces the reviewer to address each point individually rather than issue a blanket rejection.